SCHEDULE: Aterian, Inc. Shareholder Exits, Dilution Concerns

David E. Lazar files an exit amendment to Schedule 13D, reporting a decrease in beneficial ownership below 5% following the conversion of preferred stock and sale of shares, indicating significant potential dilution.

Summary

• David E. Lazar has filed an amendment to Schedule 13D, indicating he no longer beneficially owns more than 5% of Aterian, Inc.'s common stock as of September 25, 2026.
• This filing is an 'exit filing' for Schedule 13D, signifying a reduction in his stake.
• The decrease in ownership percentage is due to the conversion of Series AA Preferred Stock into 1,300,530 shares of Common Stock and a Securities Purchase Agreement (SPA) entered into on September 1, 2026.
• Under the September SPA, Lazar agreed to sell 706,100 shares of Series AA Preferred Stock and 1,750,000 shares of Series AAA Preferred Stock, convertible into an aggregate of 241,861,970 shares of Common Stock, for $12,000,000.
• These transactions, completed on September 25, 2026, represent approximately 92.50% of Aterian's outstanding common stock on a fully diluted, as-converted basis at that time.
• The filing confirms that the total number of outstanding shares of Common Stock is 261,129,410, including 1,300,530 shares from Lazar's conversion and 259,828,880 other outstanding shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant dilution implied by the conversion of preferred stock into a large number of common shares, coupled with the reporting person's exit as a significant shareholder.

Positives

• The company has secured $12,000,000 in proceeds from the sale of preferred stock.
• The transactions were completed in reliance on exemptions from registration under the Securities Act (Section 4(a)(7) and Regulation S).
• The company's common stock is listed on Nasdaq, and it is stated to be in compliance with listing requirements, with preparations to cure any potential bid price deficiency.

Negatives

• The conversion of preferred stock and sale of shares by David E. Lazar results in a significant dilution of existing common shareholders.
• The filing indicates Lazar has exited his position as a significant beneficial owner (below 5%).
• The sale of preferred stock convertible into over 241 million common shares represents approximately 92.50% of the fully diluted, as-converted common stock, indicating substantial dilution.

Risks

• Potential for significant share price volatility due to the large number of shares being converted and sold.
• The substantial increase in the number of outstanding shares could negatively impact earnings per share and shareholder value if not accompanied by proportional revenue growth.
• The reliance on exemptions from registration for the sale of securities may limit liquidity for the purchasers in the short term.

Future Outlook

The filing primarily reports on past transactions and a change in beneficial ownership. It does not contain specific forward-looking guidance from the company regarding future financial performance or strategic initiatives.

Management Comments

• The filing is an amendment to a Schedule 13D, primarily reporting factual changes in beneficial ownership and the completion of a securities purchase agreement.
• The reporting person, David E. Lazar, states that this amendment constitutes an 'exit filing' with respect to Schedule 13D due to a decrease in beneficial ownership below 5%.

Industry Context

StockSavvy.ai notes that this filing reflects a common scenario in the capital markets where significant holders of preferred stock convert their holdings and/or sell them, often leading to substantial dilution for common shareholders. The use of Section 4(a)(7) and Regulation S indicates private placements to accredited and non-U.S. investors, respectively, which are typical for such transactions.

Comparison to Industry Standards

• The conversion of preferred stock into a large volume of common stock, as seen in this filing (241,861,970 shares representing ~92.50% of fully diluted shares), is a significant dilutive event. Industry standards for preferred stock conversion typically aim to balance capital needs with minimizing immediate, drastic dilution.
• The $12 million capital raise through preferred stock sale is a moderate amount for a company of Aterian's size, but the conversion ratio implies a low effective price per share for the underlying common stock, which is a common characteristic of such financing rounds.
• The reliance on Regulation S for offshore sales and Section 4(a)(7) for accredited investors is standard practice for private placements seeking exemptions from SEC registration requirements.

Stakeholder Impact

• Shareholders: Existing shareholders face significant dilution due to the conversion of preferred stock into a large number of common shares, potentially impacting their ownership percentage and per-share value.
• Purchasers of Preferred Stock: These investors are acquiring securities that will convert into a substantial portion of the company's common stock, potentially giving them significant influence.
• Company Management: The company has received $12 million in capital, but must now manage a significantly larger base of common shareholders and address potential dilution concerns.

Next Steps

• The filing marks an 'exit filing' for David E. Lazar, indicating his reduced stake.
• The purchasers of the preferred stock will hold securities convertible into a significant portion of Aterian's common stock.

Key Dates

Recommendation

The filing indicates a significant dilutive event and the exit of a major shareholder, which are negative factors. However, the company did raise $12 million in capital. Given the mixed signals and the need for further information on how the company will leverage the capital and manage dilution, a 'hold' recommendation is prudent for existing investors, while new investors should exercise caution due to the dilution risk.

Keywords

Aterian, Schedule 13D, Securities Purchase Agreement, Preferred Stock, Common Stock, Dilution, David E. Lazar, Exit Filing